AC Immune (NASDAQ:ACIU) Trading Down 4.4% – Time to Sell?

AC Immune SA (NASDAQ:ACIU) shares dropped 4.4% on Wednesday . The company traded as low as $2.75 and last traded at $2.80. Approximately 71,081 shares were traded during trading, a decline of 45% from the average daily volume of 128,556 shares. The stock had previously closed at $2.93.

Analyst Upgrades and Downgrades

Several research firms have commented on ACIU. StockNews.com downgraded shares of AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of AC Immune in a research report on Friday, November 15th.

AC Immune Trading Down 2.9 %

The firm has a market cap of $269.12 million, a price-to-earnings ratio of -5.91 and a beta of 1.29. The business’s 50-day simple moving average is $3.05 and its two-hundred day simple moving average is $3.31.

Hedge Funds Weigh In On AC Immune

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Capital Wealth Advisors bought a new position in shares of AC Immune in the 2nd quarter worth $56,000. China Universal Asset Management Co. Ltd. increased its position in shares of AC Immune by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after purchasing an additional 7,400 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of AC Immune during the 2nd quarter valued at $218,000. Geode Capital Management LLC increased its position in shares of AC Immune by 6.4% during the 3rd quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock valued at $220,000 after purchasing an additional 3,499 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of AC Immune by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after purchasing an additional 136,300 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.